Australian Women Wanted for Clinical Study on Ovarian Cancer Diagnostic Test

Each year, over 800 women in Australia die from ovarian cancer. That may not “sound like a large number”, but considering how often this disease is diagnosed at an advanced stage because patients are often “asymptomatic” (without symptoms), a test that allows earlier ovarian cancer detection is important.

HealthLinx is an Australian biotech company that had licensed the technology from The Royal Women’s Hospital and University of Melbourne, codevelopers of the test. The company is seeking 3000 women for clinical trials of this blood test (via finger prick) to detect ovarian cancer. The clinical trial has also Women’s Cancer Foundation’s Ovarian Cancer Institute and ARL Pathology as collaborators.

Although this test targets mid- to late-stage disease, data is promising for detecting early stage.

And early stage detection is what we need most for this (and any) cancer type!